Toggle Main Menu Toggle Search

Open Access padlockePrints

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia (Cancer Cell International, (2023), 23, 1, (202), 10.1186/s12935-023-03057-8)

Lookup NU author(s): Dr Hayden Bell, Dr Helen BlairORCiD, Mankaran Singh, Professor Anthony MoormanORCiD, Professor Olaf Heidenreich, Dr Frederik van DelftORCiD, Emeritus Professor John Lunec, Professor Julie IrvingORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2025. In this article [1], Fig. 6 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the old incorrect and correct versions are displayed below. The original article has been corrected. Incorrect Fig. 6: Fig. 6 AZD1775 abrogates the intra-S-phase checkpoint and augments cell death induced by cytarabine. A A TP53 isogenic NALM6 cell line model was treated for 24 h with AZD1775 (200 nM), AraC (15 nM), or their combination and subjected to dual cell cycle and pHH3 (mitotic cells) analysis using flow cytometry. Data are representative of three independent experiments. 2 N DNA content indicates cells in G0 or G1 phase. 4 N DNA content indicates cells in either G2 or M phase. Mitotic index was determined for cells with 4 N and < 4 N DNA content. Boxes indicate pHH3 + populations. Error bars show mean SD of at least three independent experiments. Top, PI alone; bottom, pHH3/PI. B Immunoblot of apoptotic and cell cycle markers in NALM6 cells treated for 24 h with AZD1775 (200 nM), AraC (15 nM), or their combination. Images are representative of three independent experiments. C Immunoblot of apoptotic and cell cycle markers in three relapsed PDX samples treated with respective IC50s of AZD1775, AraC, or their combination for 24 h. N = 1 for each respective sample. In B and C, ɑ-tubulin was used as loading control Correct Fig. 6: AZD1775 abrogates the intra-S-phase checkpoint and augments cell death induced by cytarabine. A A TP53 isogenic NALM6 cell line model was treated for 24 h with AZD1775 (200 nM), AraC (15 nM), or their combination and subjected to dual cell cycle and pHH3 (mitotic cells) analysis using flow cytometry. Data are representative of three independent experiments. 2 N DNA content indicates cells in G0 or G1 phase. 4 N DNA content indicates cells in either G2 or M phase. Mitotic index was determined for cells with 4 N and < 4 N DNA content. Boxes indicate pHH3 + populations. Error bars show mean SD of at least three independent experiments. Top, PI alone; bottom, pHH3/PI. B Immunoblot of apoptotic and cell cycle markers in NALM6 cells treated for 24 h with AZD1775 (200 nM), AraC (15 nM), or their combination. Images are representative of three independent experiments. C Immunoblot of apoptotic and cell cycle markers in three relapsed PDX samples treated with respective IC50s of AZD1775, AraC, or their combination for 24 h. N = 1 for each respective sample. In B and C, ɑ-tubulin was used as loading control.


Publication metadata

Author(s): Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE

Publication type: Note

Publication status: Published

Journal: Cancer Cell International

Year: 2025

Volume: 25

Online publication date: 07/11/2025

Acceptance date: 02/04/2018

ISSN (electronic): 1475-2867

Publisher: BioMed Central Ltd

URL: https://doi.org/10.1186/s12935-025-04021-4

DOI: 10.1186/s12935-025-04021-4


Share